➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Medtronic
Merck
Express Scripts
Colorcon

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

APOMORPHINE HYDROCHLORIDE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for apomorphine hydrochloride and what is the scope of patent protection?

Apomorphine hydrochloride is the generic ingredient in two branded drugs marketed by Sunovion Pharms Inc and Mdd Us, and is included in two NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Apomorphine hydrochloride has two hundred and forty-two patent family members in twenty-four countries.

There are six drug master file entries for apomorphine hydrochloride. Two suppliers are listed for this compound.

Summary for APOMORPHINE HYDROCHLORIDE
Recent Clinical Trials for APOMORPHINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, LillePhase 1/Phase 2
Western University, CanadaN/A
Alexza Pharmaceuticals, Inc.Phase 1

See all APOMORPHINE HYDROCHLORIDE clinical trials

Pharmacology for APOMORPHINE HYDROCHLORIDE
Drug ClassDopaminergic Agonist
Mechanism of ActionDopamine Agonists
Medical Subject Heading (MeSH) Categories for APOMORPHINE HYDROCHLORIDE

US Patents and Regulatory Information for APOMORPHINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for APOMORPHINE HYDROCHLORIDE

Country Patent Number Estimated Expiration
China 101346135   Start Trial
Japan 2009507854   Start Trial
European Patent Office 1968558   Start Trial
Denmark 1799453   Start Trial
World Intellectual Property Organization (WIPO) 03030881   Start Trial
Canada 2447596   Start Trial
World Intellectual Property Organization (WIPO) 2011143424   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Moodys
Colorcon
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.